Infectious Diseases Clinical Trial
Official title:
Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1
Verified date | July 2022 |
Source | Carecubes, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a human non-significant risk (NSR) clinical study designed to objectively and participatively verify that the Carecube Negative Pressure Isolation Chamber is a safe and non-hostile environment for the patients that will be contained within the chamber during normal operations.
Status | Completed |
Enrollment | 11 |
Est. completion date | June 18, 2022 |
Est. primary completion date | June 18, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 64 Years |
Eligibility | Inclusion Criteria: Male, female, non-binary between the ages of 19-65 No existing medical condition that would impact the Subject from staying within the containment system for the specified time-period. Patient is not pre-dispositioned for claustrophobia Exclusion Criteria: Subjects that have a pre-existing condition of claustrophobia Subjects that have a history of hypertension Subjects with a clinical diagnosis of generalized anxiety disorder (GAD) Subjects with a clinical diagnosis of major depressive disorder (MDD) Morbidly obese patients (BMI above 40) Subjects who are Women of Child Bearing Potential (WOCBP) who either are pregnant or suspect they are pregnant |
Country | Name | City | State |
---|---|---|---|
United States | UNMC | Omaha | Nebraska |
Lead Sponsor | Collaborator |
---|---|
Carecubes, Inc. | University of Nebraska |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body Temperature | Subject's body temperature maintains a normal healthy value based on their entry body temperature and outside the Carecube | 4 hours | |
Primary | Blood Pressure | Subject's blood pressure stays at a normal healthy level with respect to their initial baseline | 4 hours | |
Primary | Pulse | Subject's pulse stays within a normal healthy level based with respect to their initial baseline | 4 hours | |
Primary | Oxygen levels | Subject's Oxygen levels stays within a normal healthy level based with respect to their initial baseline | 4 hours | |
Primary | Movement | Subject is able to move within the Carecube, to include activities such as sitting up, laying down, rotating, foot flexion or other body positioning within the hospital bed located within the Carecube. | 4 hours | |
Primary | Communication | Subject and provider are able to clearly and effectively communicate while the Subject is positioned within the Carecube Negative Pressure Isolation Chamber. | 4 hours | |
Primary | Environmental Condition | Environment does not have an elevation of temperature, Carbon Dioxide and humidity outside a normal range as compared to the external environment of the chamber. | 4 hours | |
Secondary | Comfort | Subject does not become uncomfortable or claustrophobic | 4 hours | |
Secondary | Anxiety | Subject does not become anxious | 4 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02763345 -
The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi
|
N/A | |
Completed |
NCT00550706 -
Drug Utilization Prevalence in a Pediatric Care Medical Center
|
N/A | |
Completed |
NCT01033799 -
Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers
|
N/A | |
Completed |
NCT00761462 -
BAY 0 9867 Cipro Pediatric Use Study (QUIP)
|
Phase 3 | |
Completed |
NCT05088421 -
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00828971 -
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs
|
Phase 3 | |
Recruiting |
NCT02162966 -
Safety and Efficacy Study of High Dose Colistin
|
Phase 4 | |
Recruiting |
NCT00001281 -
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
|
||
Active, not recruiting |
NCT02654210 -
LoewenKIDS - Infections and the Development of the Immune System
|
||
Completed |
NCT02226263 -
Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics
|
Phase 2 | |
Terminated |
NCT00211471 -
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
|
Phase 2 | |
Active, not recruiting |
NCT04342702 -
A Study on the Prospective Cohort Library of COVID-19 in Southeran
|
||
Completed |
NCT02134548 -
Sensitivity Study of Diagnostic for Detection of Chagas Infection
|
N/A | |
Active, not recruiting |
NCT01611025 -
Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time
|
N/A | |
Completed |
NCT01361997 -
Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination
|
Phase 3 | |
Completed |
NCT00638677 -
Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier
|
Phase 4 | |
Completed |
NCT02434848 -
A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses
|
Phase 2/Phase 3 | |
Completed |
NCT02544139 -
Specificity Study of Diagnostic for Chagas Disease
|
N/A | |
Completed |
NCT00276198 -
Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants
|
Phase 3 | |
Completed |
NCT02111564 -
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
|
Phase 3 |